Seed Healthcare has led a strategic investment in Diadem to support US commercialization of AlzoSure Predict, a blood-based Alzheimer’s diagnostic recently validated in over 900 patients and designated a Breakthrough Device by the FDA.
VolitionRx reports its finger-prick lateral flow prototype for sepsis shows strong correlation with its automated Nu.Q NETs assay, supporting point-of-care nucleosome testing for critically ill patients.
The funding will support the expansion of the Syn-One Test, a skin biopsy-based laboratory developed test for neurodegenerative diseases.
A Siemens Healthineers–commissioned survey found 82% of healthcare executives considered expanding lab services, with modernization and AI upgrades seen as top priorities for supporting organizational goals.
Read More
The IRIS TX-100 uses cartridge-based technology to measure up to 100 biomarkers in approximately 10 minutes.
Read More
The research-use-only platform combines imaging, software, and multiplex protein analysis into a standard 96-well workflow designed to simplify biomarker research.
Read More
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
Read More
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
Read More
The program connects researchers with certified laboratories offering single-molecule PCR testing, technical support, and bioinformatics expertise.
Read More
NanoSomiX and Beckman Coulter Diagnostics have partnered to develop automated blood-based immunoassays for detecting neurodegenerative disease biomarkers, aiming to enable scalable testing in clinical and research laboratories.
Read More
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
Read More
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Read More
Labcorp will pay $14.5 million to settle DOJ allegations it billed Medicare for medically unnecessary urine drug tests by submitting claims for both presumptive and definitive testing on the same sample between 2018 and 2023.
Read More
The deal adds a blood-based test for viral-mediated cancers to the company’s portfolio of transplant and cell therapy services.
Read More
The insurer will provide coverage for the multi-analyte test starting July 2026, following new data showing parity with mass spectrometry.
Read More
Anthem Blue Cross and Blue Shield will cover C2N Diagnostics’ PrecivityAD2 blood test for Alzheimer’s disease evaluation starting Oct 1, 2026, expanding access to the diagnostic tool for adults with cognitive decline.
Read More
The NASHnext assay, powered by GENFIT’s NIS4 technology, is designed to identify patients with at-risk MASH through a blood draw ordered via the Labcorp OnDemand platform.
Read More
Freenome’s updated SimpleScreen CRC blood test met all primary and secondary endpoints in clinical validation, with improved sensitivity for precancerous lesions and colorectal cancer.
Read More